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Abstract
Background: Stage is a key predictor of cancer survival. Complete cancer staging is vital for understanding outcomes
at population level and monitoring the efficacy of early diagnosis initiatives. Cancer registries usually collect details of
the disease extent but staging information may be missing because a stage was never assigned to a patient or
because it was not included in cancer registration records. Missing stage information introduce methodological
difficulties for analysis and interpretation of results. We describe the associations between missing stage and
socio-demographic and clinical characteristics of patients diagnosed with colon, lung or breast cancer in England
in 2013. We assess how these associations change when completeness is high, and administrative issues are
assumed to be minimal. We estimate the amount of avoidable missing stage data if high levels of completeness
reached by some Clinical Commissioning Groups (CCGs), were achieved nationally.
Methods: Individual cancer records were retrieved from the National Cancer Registration and linked to the
Routes to Diagnosis and Hospital Episode Statistics datasets to obtain additional clinical information. We used
multivariable beta binomial regression models to estimate the strength of the association between socio-
demographic and clinical characteristics of patients and missing stage and to derive the amount of avoidable
missing stage.
Results: Multivariable modelling showed that old age was associated with missing stage irrespective of the
cancer site and independent of comorbidity score, short-term mortality and patient characteristics. This
remained true for patients in the CCGs with high completeness. Applying the results from these CCGs to the
whole cohort showed that approximately 70% of missing stage information was potentially avoidable.
Conclusions: Missing stage was more frequent in older patients, including those residing in CCGs with high
completeness. This disadvantage for older patients was not explained fully by the presence of comorbidity. A
substantial gain in completeness could have been achieved if administrative practices were improved to the
level of the highest performing areas. Reasons for missing stage information should be carefully assessed
before any study, and potential distortions introduced by how missing stage is handled should be considered
in order to draw the most correct inference from available statistics.
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Background
Stage at diagnosis is a key predictor of cancer survival: a
higher stage is associated with lower survival. Besides its
relevance for the clinical management of individual pa-
tients, good quality and complete cancer staging is vital
for understanding outcomes at population level and moni-
toring the efficacy of early diagnosis initiatives [1–3].
Tumour staging is usually done through clinical inves-
tigations, such as imaging, and/or diagnostic or surgical
procedures aimed at determining the pathological exten-
sion of the tumour.
The Tumour Node Metastasis (TNM) classification
[4], maintained and periodically updated by the Inter-
national Union for Cancer Control (UICC), is an inter-
national standard for determining disease extension and,
ultimately, treatment options. It is based on the combin-
ation of three components: size and extent of the pri-
mary tumour (T), nodal involvement (N) and presence
or absence of distant metastasis (M). Population-based
cancer registries usually collect these details of the
disease extent to derive a TNM stage grouping, however
the completeness of this stage information may vary by
cancer site and by registry.
Missing stage information introduces methodological
difficulties for analysis, and for interpretation of results.
Understanding the characteristics of patients with miss-
ing stage and the mechanisms behind missing data is
crucial to evaluating the potential extent of bias and to
reaching sensible conclusions.
Stage information may be missing either because it
was never assigned or because it was not documented in
cancer registration records. In the first case, the lack of
stage may result from an incomplete staging assessment
that in turn may be associated with socio-demographic
and clinical characteristics of the patient. Previous re-
search carried out in England, Europe, and the United
States has reported that the proportion of unstaged
cancers is higher in certain subgroups of the population
such as the elderly [5–8], those with high levels of
comorbidity or complex care needs, and those in institu-
tionalised settings [9–12]. Race, gender, marital status,
place of residence, and receipt of surgical treatment have
also been associated with missing stage [5, 13, 14].
Patients’ refusals to undergo staging investigation proce-
dures may also contribute to missing information. In
certain settings such as England, patients diagnosed and/
or treated exclusively in private hospitals are also less
likely to have their data captured by the national registry
system. Under all of these scenarios, stage information is
plausibly missing at random (MAR): that is, the probability
for the stage to be missing is not related to the stage itself
(e.g. advanced stage), but conditional on other characteris-
tics of the patients (e.g. age, comorbidity, deprivation) [15].
Instead, if the only cause for missing stage were the
presence of obvious metastatic disease or direct referral to
palliative care, it would be more likely that stage data are
missing not at random (MNAR). This means that, even
after accounting for observed patients’ characteristics,
there will still be systematic differences in the stage
distribution between those with complete and missing
stage information.
In some instances, although stage may have been
known to the clinician or recorded in the clinical notes,
it was not reported to the cancer registry. Errors in cod-
ing of the data or failures in the recording system can
contribute to lack of stage reporting. When administra-
tive or communication issues are the cause of missing
data, the stage information is likely to be missing com-
pletely at random (MCAR) at regional and national level,
meaning that the missing data can be considered to be a
random subset of the data. In these cases, the exclusion
of the records with missing values from the analysis
(complete case analysis) would still produce unbiased
estimates, but it would lead to a loss of statistical
power and to a corresponding increase in variance.
Improving stage completeness has been a priority in
recent years in England, with financial and human re-
sources being invested to increase stage reporting to the
cancer registry. Actions have included the improvement
of the IT systems at hospitals and registries, the assign-
ment of data liaison teams to go into hospitals to investi-
gate and improve data collection practices, and the
introduction of standardised collection and recording
procedures. As an illustration, completeness of stage was
about 70% for patients diagnosed with non-small cell
lung cancer between 2004 and 2007 [16]. In 2012, stage
completeness reached 80–90% for patients diagnosed
with one of the four major cancers (colorectal, lung,
breast, and prostate) [17]. Since 2014, the percentage of
newly diagnosed cancers recorded with a valid stage has
been a quality indicator for Clinical Commissioning
Groups (CCGs), the National Health Service (NHS)
units in which cancer services are budgeted and planned
in England [18]. Although CCGs are not directly respon-
sible for collecting cancer data, they can be considered
as proxies for the registration practices of the hospital
trusts in the areas for which they commission services.
Despite recent improvements, there remains a propor-
tion of patients for whom there is no valid stage infor-
mation in the cancer registration data. In this study, we
aim to describe the socio-demographic and clinical char-
acteristics of patients diagnosed with colon cancer, non-
small cell lung cancer or breast cancer in England in
2013, for whom stage information was not available in
the cancer registration data. We describe geographical
patterns of completeness, and investigate whether the
association between patients’ characteristics and missing
stage information differs when completeness is high. We
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also estimate the number of patients who might have
been assigned a stage if the highest levels of complete-
ness were achieved throughout the country. Finally, we
use multiple imputation to estimate the likely stage
distribution of patients with missing stage.
Methods
All patients aged 15–99 years diagnosed with a primary,
invasive, malignant colon cancer (International Classifi-
cation of Diseases, ICD-10 C18), non-small cell lung
cancer (ICD-10 C34, lung cancer hereafter), and all
women diagnosed with breast cancer (ICD-10 C50) in
England in 2013 were identified in the national cancer
registration system [19]. These three cancer sites were
chosen as they are among the most common malignan-
cies, but have different prognosis, age and stage distribu-
tions at presentation.
Data sources and specification
Individual cancer records were retrieved from the Na-
tional Cancer Registration and Analysis Service (NCRAS)
through the Cancer Analysis System (CAS). This database
collates multiple cancer sources and contains various
pieces of information about the tumour stage. In the
present study, we used the ‘registry-derived stage’, a TNM
stage grouping variable derived by NCRAS using internal
procedures from available pathological and clinical
information. This variable is generally used in institu-
tional reporting in England. Whether or not a patient
had a valid registry-derived stage in their record was
the outcome of interest.
National cancer registration data in England include
quality-checked information on each patient’s date of
birth, gender, vital status, follow-up dates, tumour
morphology, the former regional registry under which
the cancer case was registered (the eight former regional
registries merged into a single national one in 2013), and
the postcode of residence at the time of diagnosis. Post-
code was used to map patients to a small geographical
region, the Lower layer Super Output Area (LSOA), and
to assign them to a CCG and to one of the five eco-
logical deprivation quintiles, derived from the income
domain of the Index of Multiple Deprivation for England
[20]. The least deprived quintile is coded to 1, and the
most deprived to 5. As there were no clear or consistent
gradients across these five categories and numbers in
some categories were small in some CCGs, we further
grouped patients into two categories: more affluent
(quintiles 1 and 2), and more deprived (quintiles 3, 4
and 5). We derived a variable as an indicator of short-
term mortality based on the vital status of each patient
at 30 days after diagnosis.
Individual tumour observations were linked to the
Routes to Diagnosis (RtD) dataset [21] in order to classify
patients into two groups according to whether they were
diagnosed through an emergency admission or not, and to
the Hospital Episode Statistics (HES) dataset in order to
acquire additional clinical information. We applied an
algorithm developed by Maringe et al. [22] to the HES
dataset to obtain information on prevalent comorbidities
diagnosed up to six years before the cancer diagnosis (ex-
cluding the six months preceding the cancer diagnosis as
they might have been a consequence of the tumour itself)
which were then summarised into the Charlson Comorbid-
ity Index (CCI). This index assigns patients an overall score
composed of a sum of severity-weighted values given to 17
specific chronic conditions [23]. We defined three
levels of comorbidity according to the overall score
(low = 0; medium = 1–2; high ≥3). Patients were classi-
fied as having received surgery if they were recorded in
HES as having undergone a cancer-related procedure
up to six months after the cancer diagnosis.
Statistical analyses
In the descriptive analyses, a chi-squared test was used
to test for significant differences between patients with
and without stage information for each of the inde-
pendent variables.
One-year stage-specific net survival was calculated
using the Pohar-Perme estimator, which accounts for
competing risks of death from other causes with increas-
ing age via inverse probability weighting [24], using the
standard cohort approach and follow-up to 31/12/2014
[25]. Mortality from other causes by age and sex was
drawn from region- and deprivation-specific life tables
for England for 2013 and 2014 [26]. An additional miss-
ing stage category was included in the stratified analysis.
In order to enable comparison between stages, estimates
were age-standardised using the International Cancer
Survival Standards (ICSS) weights, for which age at diag-
nosis was categorised into five groups (15–44, 45–54,
55–64, 65–74, and 75–99 years) [27].
In order to account for the potential variability in the
outcome between the 209 CCGs, we used multivariable
beta binomial regression models [28, 29] to estimate the
odds ratios (OR) for the association between socio-
demographic and clinical characteristics of patients and
missing stage. Two sets of models, each containing all
the socio-demographic and clinical variables available,
were built. Firstly, models included all patients diag-
nosed in 2013 in order to understand what factors were
associated with missing stage (Model 1). Secondly, ana-
lyses were restricted to CCGs with a low proportion of
missing stage data amongst their patients, to allow fur-
ther investigation of which patient factors remained as-
sociated with missing stage in areas with high
completeness (Model 2). In these areas we assumed that
patient characteristics were the main determinants of
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missing data, while administrative or communication is-
sues played a marginal role. These were the CCGs for
which the percentage of missing stage data was below
the 10th percentile of the distribution across all CCGs
(8.2% for colon, 5.2% for lung, and 4.7% for breast can-
cer). We tested for interactions between various patient
characteristics and we did not find any statistically sig-
nificant interaction apart from an effect modification be-
tween age and comorbidities among women diagnosed
with breast cancer. Since this interaction only slightly
changed the estimates and was non-significant in the
model restricted to CCGs with high completeness
(Model 2), we only reported the results from the main
models (without interactions).
A question of interest was whether the proportion of
missing stage would have changed if the missingness
patterns of the areas with high completeness were
applied. To achieve that, the parameter estimates from
the Model 2 for the restricted sample of CCGs with high
completeness of stage data were applied to the various
covariate patterns on the full cohort in order to calculate
the number of patients who might have been expected
to have valid data on stage. The expected number of
patients with missing stage data was then subtracted
from the observed number to provide an estimate of the
number and proportion of patients for whom missing
data on stage was potentially avoidable, if they had had
the same chance of being staged as the patients in CCGs
with high completeness where administrative issues were
assumed to be minimal.
Under the assumption that stage was missing at ran-
dom, we estimated the likely stage distribution of pa-
tients with missing stage using multiple imputation. As
the proportion of missing stage was never above 20%, 20
imputed datasets for each cancer site were produced
using the mi impute Stata command and a multinomial
logistic modelling approach that included all the vari-
ables used in the analysis as well as the morphological
subtype (for breast cancer), the former regional cancer
registry, the event indicator and the Nelson-Aalen esti-
mator of the cumulative hazard of death [15]. Analyses
were conducted using Stata 14 [30].
Results
The study population consisted of 21,522 colon can-
cer patients, 31,188 lung cancer patients, and 41,657
women with breast cancer diagnosed in England in
2013. The proportion of patients with missing stage
information was 18.5% for colon, 12.6% for lung and
15.6% for breast cancer.
For each cancer, data on stage were more often missing
for older patients (youngest versus oldest age group: 15%
vs 32% for colon, 10% vs 22% for lung, 13% vs 38% for
breast cancer), for those who were diagnosed through an
emergency route, who died within 30 days of diagnosis
(patients who survived more than 30 days versus patients
who died within 30 days: 17% vs 37% for colon, 10% vs
25% for lung, 15% vs 48% for breast cancer), those who
did not have record of cancer-directed surgery, or who
had concomitant chronic conditions (Table 1). For pa-
tients with cancers of the lung or breast, the proportion
with missing stage was significantly higher among more
deprived patients. For colon cancer, the proportion was
higher among women than men.
Age-standardised one-year net survival among patients
without a valid stage was 72% for colon, 36% for lung
and 92% for breast cancer (Table 1). For colon and lung
cancer patients, survival estimates of these were between
those of patients diagnosed with stage III and stage IV
tumours. Survival of women diagnosed with breast can-
cer and with missing stage was closer to that seen in pa-
tients with stage III breast cancer.
There was substantial variation in the proportion of
patients with missing stage between the 209 CCGs: the
range was 0–63% for colon, 2–62% for lung, and 2–58%
for breast cancer (Fig. 1).
For each cancer site, findings for the whole cohort
(Model 1, point estimates mutually adjusted for all the
other covariates) indicate that increasing age was associ-
ated with missing stage information: patients aged 85 or
older had approximately twice the odds of missing stage
compared with patients aged 15–64 (colon cancer: OR =
1.8, 95%CI 1.6–2.1; lung cancer: OR = 2.1, 95%CI 1.4–2.
4; breast cancer: OR = 2.2, 95%CI 1.8–2.6). Additionally,
patients who died shortly after diagnosis and those who
had a high Charlson comorbidity score were less likely
to have stage information, while those who underwent a
surgical procedure were more likely to have been staged.
Among women with breast cancer, being diagnosed
through an emergency admission was associated with a
24% increase in the odds of missing stage (OR = 1.24,
95%CI 1.1–1.5) compared with patients admitted by
other routes. The odds of having missing stage infor-
mation were 20% lower among more deprived women
with breast cancer than among more affluent women
(OR = 0.8, 95%CI 0.7–0.9) (Table 2).
In CCGs with high stage completeness (Model 2, point
estimates mutually adjusted for all the other covariates),
the association between missing stage information and
older age of patients remained significant and increased
in strength for all three cancers (colon: OR = 2.8, 95%CI
1.4–5.5; lung: OR = 2.8, 95%CI 1.5–5.2; breast: OR = 3.7,
95%CI 2.1–6.5). Undergoing a surgical procedure
remained negatively associated with missing stage
among colon and breast cancer patients. Conversely,
short-term mortality almost doubled the odds of having
missing stage for lung and breast cancer patients, but
did not have a significant effect for colon cancer.
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If the whole cohort had had the probability of missing
stage seen in CCGs with high completeness (low admin-
istrative issues), an additional 64, 71 and 74% of patients
with missing stage for colon, lung and breast cancer, re-
spectively, could potentially have been staged in 2013 in
England (Table 3). That equates to over 10,000 out of
95,000 patients diagnosed with one of these cancers.
Figure 2 shows the stage distribution under different
scenarios, before and after multiple imputation. For each
cancer, the stage distribution after imputation among
patients with missing stage (third bar) was slightly more
advanced (lower average proportion of cases in stage I and
higher proportion of cases in stage IV) in comparison to
the stage distribution for patients with known stage (first
bar), and to the stage distribution after imputation of all
patients in the cohort (second bar). The imputed stage
distribution for patients with missing stage tended to-
wards even later stages among the patients in the CCGs
with high completeness (fourth bar), especially for colon
and to a lesser extent for lung and breast cancer.
Discussion
The proportion of missing stage information for colon,
lung and breast cancer patients diagnosed in England in
2013 varied by socio-demographic and clinical character-
istics and by geography. Multivariable modelling showed
Table 1 Distribution of patients with missing stage information, and net survival by stage, England, 2013
Colon cancer Non-small cell lung cancer Breast cancer
No. Missing stage (%) No. Missing stage (%) No. Missing stage (%)
All patients 21,522 18.5 31,188 12.6 41,657 15.6
Age at diagnosis
15–64 5566 15.1 * 6890 9.7 * 22,611 12.7 *
65–74 6024 14.5 10,161 9.9 9376 11.5
75–84 6798 18.6 10,008 13.4 6393 20.4
85+ 3134 32.1 4129 22.4 3277 38.3
Sex
Male 11,316 17.6 * 17,004 12.3
Female 10,206 19.6 14,184 13.0
Income deprivation group
More affluent 9489 18.7 9769 13.5 * 18,771 16.9 *
More deprived 12,033 18.4 21,419 12.2 22,886 14.6
Emergency presentation
No 15,248 17.3 * 20,549 10.8 * 40,137 15.1 *
Yes 6274 21.5 10,639 16.0 1520 31.1
Death within 30 days of diagnosis
No 19,973 17.1 * 25,919 10.1 * 41,273 15.3 *
Yes 1549 36.5 5269 24.8 384 48.4
Surgical procedure
No 3403 35.7 * 26,410 13.7 * 9450 37.4 *
Yes 18,119 15.3 4778 6.8 32,207 9.3
Charlson comorbidity index
0 15,913 17.1 * 19,398 12.1 * 34,782 14.6 *
1–2 4009 21.3 8478 12.7 5376 18.9
> =3 1600 25.6 3312 15.7 1499 28.2
One-year net survival (NS %, 95% CI)
Stage I 0.98 (0.98–0.99) 0.88 (0.87–0.89) 1.00 (1.00–1.01)
Stage II 0.95 (0.94–0.96) 0.73 (0.71–0.75) 1.00 (0.99–1.00)
Stage III 0.89 (0.89–0.90) 0.48 (0.47–0.50) 0.96 (0.95–0.97)
Stage IV 0.44 (0.42–0.45) 0.20 (0.19–0.20) 0.67 (0.65–0.67)
Missing stage 0.72 (0.70–0.74) 0.36 (0.34–0.37) 0.92 (0.92–0.93)
*p-value from chi-squared test ≤0.05
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that old age was associated with missing stage irrespect-
ive of the cancer site and independent of comorbidity
score, short-term mortality and patient characteristics.
This remained true for patients in the CCGs with high
completeness, where administrative issues were likely to
be minimal. Approximately 70% of the missing data was
potentially avoidable if all patients had had the same
chance of being staged as the patients in those CCGs.
A strength of this study is that it draws upon a
population-based, high-quality cancer registration sys-
tem that covers the entire English population, minimis-
ing the risk of selection bias. Furthermore, we were able
to control for receipt of surgery and for comorbidity
through linkage with secondary care data (HES) data.
The latter is particularly relevant for elderly patients as
it allows to distinguish between clinical decisions based
on the presence of concurrent chronic conditions (that
may contraindicate staging investigations), and decisions
Fig. 1 Distribution of the proportion of missing stage by Clinical
Commissioning Group, England, 2013
Table 2 Adjusted Odds Ratios with 95% Confidence Intervals for missing stage by patient characteristics, England, 2013
Cancer patients
Colon cancer Non-small cell lung cancer Breast cancer
Model 1a Model 2 b Model 1a Model 2 b Model 1 a Model 2 b
OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI
Age at diagnosis
15–64 1 1 1 1 1 1
65–74 0.91 (0.80–1.03) 0.78 (0.36–1.71) 0.98 (0.85–1.12) 0.88 (0.48–1.62) 1.13 (0.93–1.36) 1.05 (0.55–2.03)
75–84 1.13 (1.01–1.28) 1.61 (0.84–3.11) 1.21 (1.05–1.38) 1.10 (0.60–2.01) 1.46 (1.23–1.74) 1.85 (1.06–3.24)
85+ 1.84 (1.63–2.09) 2.80 (1.43–5.49) 2.08 (1.80–2.39) 2.77 (1.48–5.19) 2.15 (1.80–2.56) 3.71 (2.11–6.49)
Sex
Male 1 1 1 1
Female 1.09 (1.00–1.18) 1.49 (0.97–2.29) 1.05 (0.96–1.15) 1.11 (0.75–1.63)
Income deprivation group
More affluent 1 1 1 1 1 1
More deprived 0.98 (0.90–1.06) 1.07 (0.70–1.66) 0.91 (0.83–1.00) 1.06 (0.68–1.65) 0.81 (0.72–0.91) 0.92 (0.63–1.35)
Emergency presentation
No 1 1 1 1 1 1
Yes 0.93 (0.84–1.02) 1.01 (0.65–1.57) 0.97 (0.89–1.07) 0.50 (0.31–0.78) 1.24 (1.07–1.45) 1.23 (0.71–2.14)
Death within 30 days of diagnosis
No 1 1 1 1 1 1
Yes 1.63 (1.44–1.85) 1.26 (0.70–2.27) 2.62 (2.37–2.89) 4.91 (3.14–7.69) 1.87 (1.47–2.38) 2.55 (1.14–5.68)
Surgical procedure
No 1 1 1 1 1 1
Yes 0.44 (0.40–0.48) 0.30 (0.19–0.48) 0.68 (0.58–0.79) 0.95 (0.47–1.90) 0.23 (0.20–0.28) 0.31 (0.20–0.49)
Charlson comorbidity index
0 1 1 1 1 1 1
1–2 1.16 (1.05–1.28) 1.40 (0.86–2.29) 1.00 (0.91–1.11) 1.07 (0.69–1.67) 1.08 (0.95–1.24) 0.95 (0.61–1.46)
> =3 1.34 (1.17–1.53) 1.26 (0.65–2.42) 1.17 (1.03–1.32) 1.01 (0.55–1.84) 1.24 (1.05–1.46) 1.72 (0.98–3.03)
OR odds ratio, 95% CI 95% confidence interval
a Model including the whole sample of patients b Model including only patients in the Clinical Commissioning Groups with high stage completeness
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based solely on chronological age. Nonetheless, we ac-
knowledge that the Charlson Comorbidity Index only
captures the clinical dimension of the frailty in the
elderly [31] and does not encompass other factors (e.g.
level of disability or of health care needs) which may
also contribute to the absence of tumour stage.
The lack of publicly-available information on how
NCRAS handled missing individual T, N, and M compo-
nents in deriving the grouped stage variable used in the
analysis limited some of our interpretation. The process
of defining the grouped stage variable has a crucial
impact on the definition of stage categories and on
stage-specific survival [32]. We assumed that the derived
stage reflected the true extent of the disease, that a sys-
tematic and consistent approach was used to summarise
individual information on the extent of the tumour into
a single variable, and that the staging classification for
specific cancer sites was consistent between hospitals.
However, we could not appraise directly the possibility
of misclassification or inconsistencies.
The independent association between old age and
missing stage that was evident in our study, has also
been extensively documented by US studies using the
Surveillance, Epidemiology, and End Results database,
where completeness has been reported to be generally
high [5, 13], and in European studies based on national
or regional cancer registries with lower levels of com-
pleteness (for example, around 70% among colon cancer
patients in Denmark [9] and around 50% among lung
and colon patients in Mallorca [8]). Having accounted
for comorbidity in our study, this result may be partially
explained by the fact that elderly patients are more likely
to be cared for in institutions and, in such settings, there
may be sub-optimal provision of and access to cancer
care which could interfere with the comprehensiveness
of diagnostic and staging investigations [11]. However, a
study carried out in the United States [10] reported that
older patients were less likely to have missing stage re-
gardless of the level of care needs, measured by use of
home health care and nursing home care. Our finding
implies inequalities in comprehensive cancer care for the
elderly, which is a growing concern in the England [33].
We noted a consistent association between short-term
mortality and missing stage for lung and breast cancer
patients. Patients with poor prognosis may die before
any diagnostic investigation can be planned and/or
conducted or they may be considered to be too frail to
undergo staging investigations which require a surgical
procedure in many cases. In disentangling the relation-
ship between receipt of surgical procedures and a re-
duced likelihood of missing stage for colon and breast
cancer patients, an issue of reverse causality arises be-
cause some of these procedures had a diagnostic pur-
pose and those with a therapeutic purpose would have
been guided by stage at diagnosis.
After examining different cut-offs, we defined the
threshold of high completeness at the 10th percentile of
the distribution of missing stage across all CCGs because
it assured both a reasonable sample size and a better
than average level of completeness. This cut-off is simi-
lar to the level of completeness reached at national level
in the most recent years so the results we obtained from
our restricted analyses remain valid for the whole coun-
try [34]. The substantial gain in stage completeness we
estimated at national level (nearly 10% for the studied
cancers) represented the avoidable share of missing stage
data had all CCGs performed as well as those with the
most efficient registration practices in their correspond-
ing hospital trusts in 2013. This also suggests that the
administrative issues can be feasibly overcome and that
strengthening registration practices (e.g. improvement
of the IT systems at hospitals and registries, assign-
ment of data liaison teams and standardisation of pro-
cedures) has been effective in enhancing the stage data
completeness.
In our cohort of cancer patients, missing information
followed a pattern, whereby the probability of missing
stage was associated with certain socio-demographic and
clinical characteristics of the patients. In addition, we
observed that survival of patients with missing stage was
between the survival of patients with stage III and IV tu-
mours, and nearer to those diagnosed at stage III for
breast cancer, implying a mixture of stages and not only
late stage. In other words, at national level, missing stage
Table 3 Number (%) of observed, expected and potentially avoidable patients with missing stage information, England, 2013
Patients with missing information on stage at diagnosis
Observed Expected a Potentially avoidable a
Patients No. % No. 95% CI % No. 95% CI %
Colon cancer 21,522 3990 18.5 1433 578.7–2287.6 6.7 2557 470.2–1838.0 64.1
Non-small cell lung cancer 31,188 3935 12.6 1154 470.2–1838.0 3.7 2781 2096.9–3464.8 70.7
Breast cancer 41,657 6515 15.6 1689 838.2–2539.7 4.1 4826 3975.3–5676.8 74.1
95% CI 95% confidence interval
a The expected number are those patients for whom stage would still be missing if all patients had had the same probability of being staged as the patients in
the CCGs with the highest stage completeness. The difference between the observed and expected numbers is then the number of patients for whom missing
data on stage was potentially avoidable. Numbers are rounded up to the integer
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Fig. 2 Registry stage distribution in patients with known stage, and after multiple imputation, England, 2013. Note: percentages after multiple
imputation refer to the proportional distribution across all of the imputed datasets
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was plausibly missing at random. In such a situation,
multiple imputation represents a valid approach to han-
dle missing data in the analytical phase [35].
However, multiple imputation is computationally in-
tense and theoretically challenging therefore it may not
be extensively applied by data analysts. Alternative tech-
niques, such as single imputation or complete case
analysis are often used, especially when easy-to-interpret
routine statistics are needed in a timely and recurring
fashion. Yet, depending on the reasons for the missing
data, such or similar approaches may introduce bias or
lead to inefficient analyses [36]. For example in England,
the “missing-is-late” assumption underpins the computa-
tion of the ‘cancer diagnosed at early stage’ indicator by
CCG [37] which is reported quarterly in the cancer
dashboard, an online collection of cancer indicators
designed to support performance monitoring and im-
provement [38]. According to the likely distribution we
observed in our data, this strategy, which corresponds to
single imputation, may be a fairer approximation in
those CCGs with high completeness, where the stage
distribution was more skewed towards late stages, but it
may distort the results in the CCGs with lower com-
pleteness (survival is likely to be inflated because those
with missing information on stage who fall into the late
stage category are less likely to have late stage, in fact,
than those assigned to late stage in CCGs with high
completeness). Therefore, evaluating the ‘cancer diag-
nosed at early stage’ indicator together with a second in-
dicator reported on the dashboard, the ‘record of cancer
stage at diagnosis’, is necessary to demonstrate the extent
of the potential bias and enable correct interpretations.
Conclusions
Analyses of English population-based cancer registry
data from 2013 showed that the disadvantage in stage
completeness for the oldest patients persists even when
completeness is generally high. This does not appear to
be well determined by the presence of comorbidity. It
may be due to other issues of frailty that we were unable
to measure, or due to clinical decisions about diagnostic
procedures being based solely on the patient’s chrono-
logical age. Given that survival of the oldest cancer
patients tends to be worse in England than in other
countries [1, 39], the lack of stage data should be exam-
ined in relation to poorer outcomes among the elderly.
In 2013 there remained a substantial proportion of
‘avoidable’ missing data: we estimated that 70% of pa-
tients with missing information on stage could have had
complete data if administrative practices were improved
to the level of the highest performing areas. These
improvements have been borne out in recent years, but
researchers are still using earlier data especially where
they are looking at longer-term follow-up and therefore
they should be aware what the characteristics of patients
with missing information on stage are.
The non-random distribution of missing stage across
population strata and health geographies means that
handling missing stage in the analysis of population-
based cancer registry data sets needs careful consider-
ation to reduce the risk of bias. Possible reasons for
missing data on stage should be carefully assessed before
any study, and potential bias and distortions introduced
by how missing stage is handled should be considered
and acknowledged. In this way, the most appropriate
analyses can be chosen and the best inferences drawn
from available statistics.
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